SAVE (super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results

Charles C. Wykoff, David M. Brown, Eric Chen, James C. Major, Daniel E. Croft, Angeline Mariani, Tien P. Wong

Research output: Contribution to journal › Article

20 Scopus citations

Fingerprint Dive into the research topics of 'SAVE (super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results'. Together they form a unique fingerprint.

Medicine & Life Sciences